Study of ALN-SOD for ALS with SOD1 gene mutation
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ALS and a known SOD1 gene mutation
- Your lung function (SVC) is at least 50% of normal for your age and height
- Your BMI is 35 or less
- If you take riluzole or edaravone, the dose must be stable for at least 4 weeks before starting
- You have not had a tracheostomy or treatment with tofersen in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
This study tests an experimental treatment called RAG-17 for people with ALS who have a specific genetic change in the SOD1 gene. The goal is to see if it can slow down the disease and improve symptoms.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.